#OneCeva, Press Release
10 January 2024

Ceva Santé Animale, announces new leadership for North America

Libourne, January 10, 2024 – Ceva Santé Animale (Ceva), the #5 animal health company present in 110 countries worldwide, is pleased to announce the appointment of Brad McCollum as Senior Vice President for North America.

Brad McCollum succeeds Jean-Charles Tissot, who has been overseeing this region since 2019 and will now lead the global autogenous vaccines’ activities. Brad McCollum will lead Ceva’s business development and activities in the United States and Canada.

A graduate of the University of Oklahoma, Brad McCollum brings an impressive 25-year career in pharmaceuticals and animal health. Before joining Ceva, he served as Senior Vice President Petcare for the U.S. Business at Zoetis. His extensive leadership experience also includes different roles at Zoetis and over a decade at Pfizer.

Brad McCollum looks forward to building on Ceva’s current successes across all species and accelerating growth in the companion animal sector. He is committed to delivering efficient solutions that meet customers’ evolving needs in the US and Canada.

Brad McCollum states, “I am excited to assume the leadership of North America, committed to building on the strong legacy of providing customer value across all species. Leveraging my in-depth knowledge of the market and customer needs in North America, I am eager to continue innovating and offering novel solutions for our customers.”

Ceva, a global leader in the animal health industry, underlines its dedication to expanding its footprint in the U.S. market, with a particular emphasis on the veterinary channel, to successfully attain this objective.

Andras Bolcskei, Executive Vice President for Global Commercial Operations at Ceva underscores the company’s ambition in the pet segment: “We are determined to play in the top league in the pet market, and Brad McCollum’s appointment reinforces our commitment to innovation and efficiency to address the evolving needs of our customers.”

Collaboration in 47 countries.
You are leaving the country website to access another site in the group. Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.